RecruitingNot ApplicableNCT05186064
Glioblastoma Targeted Treatment Option Maximization by WGS
Glioblastoma Targeted Treatment Option Maximization by Whole Genome Sequencing
Sponsor
UMC Utrecht
Enrollment
160 participants
Start Date
Jul 25, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
In Dutch centers performing neurosurgery on and/or treating GBM, all recurrent GBM patients are discussed in local tumor boards and this setup will be used to effectively identify possible GLOW study candidates. 160 patients that will undergo re-resection in the GLOW study will be presented with WGS results leading to added treatment options.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Histopathologically confirmed IDH wild type glioblastoma, first recurrence after standard chemoradiation; suitable for standard-of-care re-resection;
- Age ≥ 18 years;
- Able and willing to give written informed consent;
- Life expectancy \>3 months, allowing adequate follow-up of toxicity evaluation and antitumor activity;
- KPS performance status ≥70.
Exclusion Criteria2
- Currently actively treated in another antitumor clinical trial (excluding DRUP and STELLAR studies);
- Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in medication studies or which could jeopardize compliance with study requirements including, but not limited to ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.
Interventions
DIAGNOSTIC_TESTwhole genome sequencing
whole genome sequencing will be performed on tumor material after re-resection per standard of care
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05186064
Related Trials
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
NCT061615191 location
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
NCT072256218 locations
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
Treatment Intensification With Temozolomide in Adults With a Glioblastoma
NCT0366372519 locations
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
NCT047320656 locations